Liraglutide (CAS No.: 204656-20-2) - Long-Acting GLP-1 Receptor Agonist for Type 2 Diabetes & Obesity Management

As a professional supplier of pharmaceutical-grade peptide active pharmaceutical ingredients (APIs), we provide high-purity Liraglutide that strictly complies with global pharmacopoeia standards (USP, EP, BP). A recombinant glucagon-like peptide-1 (GLP-1) receptor agonist, it mimics the action of endogenous GLP-1 to regulate blood glucose and reduce body weight-making it a core therapeutic agent for type 2 diabetes mellitus (T2DM) and chronic obesity management in adults.

Product Basic Information

Product Core Functions & Applications

Liraglutide CAS#204656-20-2 exerts its pharmacological effects by selectively activating GLP-1 receptors (expressed in the pancreas, brain, and gastrointestinal tract), which addresses key pathophysiological mechanisms of T2DM and obesity. Its key advantage is a 24-hour half-life, enabling once-daily subcutaneous administration and stable blood concentration-greatly improving patient compliance. It is exclusively used in human pharmaceutical formulations:

1. Type 2 Diabetes Mellitus (T2DM) Treatment

Monotherapy: For patients with T2DM who cannot tolerate metformin or have contraindications to first-line oral agents, it reduces fasting/postprandial blood glucose and lowers glycated hemoglobin (HbA1c) by 1.0-1.5%.

Combination Therapy: Used with metformin, sulfonylureas, SGLT2 inhibitors, or insulin to enhance glycemic control-while offsetting weight gain caused by insulin/sulfonylureas (average weight reduction of 1-3kg in combined use).

Cardiovascular Protection: Reduces the risk of major adverse cardiovascular events (MACE, e.g., myocardial infarction, stroke) in T2DM patients with established cardiovascular disease or high cardiovascular risk.

2. Chronic Obesity Management

Indicated for adults with a body mass index (BMI) ≥30 kg/m² (obesity) or BMI ≥27 kg/m² (overweight) with at least one weight-related comorbidity (e.g., hypertension, dyslipidemia, T2DM).

Achieves sustained weight loss (average 5-7% of baseline weight over 52 weeks) by suppressing appetite (via central nervous system regulation) and slowing gastric emptying-reducing food intake without severe hunger.

Dosage Forms

Injectable Formulations: Pre-filled pens (6 mg/mL, 12 mg/mL) for subcutaneous injection (abdomen, thigh, upper arm), administered once daily. The dose is gradually escalated (starting from 0.6 mg/day) to minimize gastrointestinal side effects.

Quality & Safety Assurance

as a high-potency peptide API, requires strict quality control to ensure efficacy, stability, and clinical safety:

Raw Material Sourcing & Production

Precursor Control: Uses recombinant E. coli-expressed GLP-1 analog precursors and high-purity synthetic fatty acid chains (to extend half-life via albumin binding), avoiding impurities that may affect receptor affinity or trigger immune responses.

Manufacturing Process: Produced in GMP-certified cleanrooms via solid-phase peptide synthesis (SPPS), followed by post-translational modification (fatty acid conjugation) and multi-step purification (high-performance liquid chromatography, HPLC). Strict control over coupling efficiency and deprotection steps ensures batch-to-batch consistency.

Comprehensive Testing Protocols

Each batch undergoes rigorous testing to meet global pharmacopoeia standards:

Purity & Related Substances: HPLC analysis (purity ≥99.0%, single impurity ≤0.5%, total impurities ≤1.0%).

Peptide Identity: Confirmed via mass spectrometry and amino acid sequence analysis.

Physical & Chemical Tests: Specific optical rotation (+63° to +73°, in 0.1M acetic acid), moisture content (Karl Fischer method ≤3.0%), and pH (6.0-8.0 for aqueous solution).

Safety Tests: Heavy metal detection (ICP-MS), microbial limit testing (total aerobic microbial count ≤100 CFU/g), sterility testing (for injectable-grade API), and endotoxin testing (≤0.25 EU/mg).

Safety Reminders

Common Side Effects: Gastrointestinal reactions (nausea, diarrhea, constipation, vomiting)-mostly mild to moderate, occurring in the initial dose-escalation phase and improving with continued use.

Serious Risks:

Pancreatitis: Monitor for persistent severe abdominal pain (with nausea/vomiting); discontinue immediately if suspected.

Thyroid C-Cell Tumor Risk: Contraindicated in patients with personal/family history of medullary thyroid carcinoma (MTC) or multiple endocrine neoplasia syndrome type 2 (MEN 2).

Hypoglycemia: Risk increases when combined with insulin or sulfonylureas-reduce doses of these agents by 20-50% initially and monitor blood glucose closely.

Renal Impairment: Use with caution in patients with moderate-to-severe renal dysfunction (eGFR <30 mL/min/1.73m²); avoid in end-stage renal disease.

Contraindications: Hypersensitivity to Liraglutide or any excipients; MTC history/family history; MEN 2; severe gastrointestinal disease (e.g., gastroparesis).

Cooperation & Contact

We supply pharmaceutical-grade Liraglutide CAS#204656-20-2 API for manufacturers of once-daily injectable formulations, with flexible production capacities (from gram-level R&D samples to kilogram-level bulk orders). If you are a pharmaceutical enterprise, R&D institution, or formulator in need of this product, please contact us for:

Detailed pharmacopoeia compliance documents (USP/EP monograph confirmation, certificate of analysis).

Pricing quotes, bulk order discounts, and free R&D sample requests.

Technical support (e.g., formulation compatibility, dose-escalation guidance, peptide stability maintenance).

Contact Information:

Email: sales@huarongpharma.com

Phone/WhatsApp: +86 13751168070

We adhere to the principles of "quality first, compliance-oriented" and look forward to establishing long-term, mutually beneficial cooperative relationships with global partners!

Frequently Asked Questions (FAQs)

1. What are the common side effects of Liraglutide?

The most common side effects are gastrointestinal reactions, including nausea (30-45% of patients), diarrhea (15-30%), constipation (10-20%), vomiting (5-15%), and decreased appetite (15-25%). These are typically dose-dependent, occur within the first 2-4 weeks of treatment, and often resolve with gradual dose escalation or continued use. Less common side effects include headache, fatigue, and mild injection site reactions (redness, itching).

2. How does Liraglutide work in the body?

works by mimicking endogenous GLP-1 (a gut hormone released after meals) and activating GLP-1 receptors in key organs:

Pancreas: Stimulates insulin secretion (only when blood glucose is elevated, avoiding hypoglycemia) and inhibits glucagon secretion (reduces hepatic glucose production).

Gastrointestinal Tract: Slows gastric emptying, delaying nutrient absorption and reducing postprandial blood glucose spikes.

Brain: Acts on the hypothalamus to suppress appetite and increase satiety, reducing food intake and promoting weight loss.

Long Half-Life: A fatty acid chain attached to the peptide binds to albumin in the bloodstream, slowing renal clearance and enabling once-daily administration.

3. Are there any drug interactions with Liraglutide?

Yes, is ability to slow gastric emptying may affect the absorption of other oral medications. Key interactions include:

Oral Hypoglycemic Agents: Combined use with insulin or sulfonylureas (e.g., glimepiride) increases hypoglycemia risk-reduce doses of insulin/sulfonylureas by 20-50% initially.

Oral Contraceptives: May delay absorption (peak concentration reduced by ~20%); administer contraceptives at least 1 hour before Liraglutide injection.

Antibiotics/Antifungals: Drugs requiring rapid absorption (e.g., amoxicillin, fluconazole) should be taken 1 hour before or 2 hours after Liraglutide to avoid absorption delays.

Beta-Blockers: May mask hypoglycemia symptoms (e.g., tachycardia); monitor blood glucose closely in co-administration.

Glucocorticoids: May weaken is glucose-lowering effect; increase glucose monitoring and adjust doses if needed.

Hot Tags: liraglutide cas#204656-20-2, China liraglutide cas#204656-20-2 manufacturers, suppliers